BioCardia (NASDAQ:BCDA) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

BioCardia (NASDAQ:BCDA) released its earnings results on Friday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04), FiscalAI reports.

Here are the key takeaways from BioCardia’s conference call:

• BioCardia said the CardiAMP heart failure data showed compelling benefits versus control, including reduced adverse remodeling and a statistically significant composite outcome in a high-risk biomarker subgroup.
• The company reported that Japan’s PMDA is inclined to accept the trial data as the basis for a regulatory submission and initial approval, and BioCardia is preparing a Shonin application over the next ~7 months.
• BioCardia said the FDA found the safety profile acceptable and discussed a pre-market approval pathway, while encouraging completion of the ongoing CardiAMP Heart Failure II study to support the filing.
• For its Helix delivery system, FDA indicated no safety or compatibility concerns and suggested potential approval paths, including aligning it with CardiAMP or pursuing a standalone de novo route.
• First-quarter 2026 expenses fell year over year to $2.3 million, with net loss improving to $2.3 million, but cash and cash equivalents ended at only $951,000, underscoring the company’s need for additional funding.

BioCardia Trading Down 7.3%

BCDA stock opened at $1.01 on Friday. BioCardia has a 52 week low of $1.00 and a 52 week high of $2.49. The company has a market capitalization of $11.05 million, a price-to-earnings ratio of -1.11 and a beta of 0.56. The firm’s 50-day moving average is $1.18 and its two-hundred day moving average is $1.26.

Institutional Trading of BioCardia

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cetera Investment Advisers bought a new stake in shares of BioCardia during the 2nd quarter worth about $40,000. DRW Securities LLC bought a new position in shares of BioCardia during the 4th quarter valued at about $72,000. Finally, Geode Capital Management LLC boosted its position in shares of BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares in the last quarter. 20.57% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioCardia has an average rating of “Hold” and a consensus price target of $25.00.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.